Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Expanded hemodialysis reduces the concentration of free light chains in patients with acute kidney injury in myeloma cast nephropathy
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF-α and AP-1 Signaling
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded Hemodialysis Therapy: Prescription and Delivery
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded hemodialysis: a new concept of renal replacement therapy
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded hemodialysis: is anticoagulation of the dialysis circuit different from online hemodiafiltration and high-flux hemodialysis?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded hemodialysis: Is anticoagulation of the dialysis circuit different from online hemodiafiltration and high-flux hemodialysis?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Expanded home hemodialysis: case reports
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Experience of using haemodialysis with medium cut-off dialyser in cast nephropathy
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Exploratory comparison of dialysis efficiency at different dialysate flow (Qd) in expanded hemodialysis in two centers in Colombia
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Extended versus conventional hemodialysis view or online hemodiafiltration. Comparative study of the need for heparin and coagulation of the system (enfermerianefrologica.com)
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.